Business context and reporting period
Orthofix International N.V. (the registrant named in this filing) is a global medical-device company serving spine and orthopedic markets through BioStim, Biologics, Extremity Fixation and Spine Fixation. This unaudited Form 10-Q covers the three months ended March 31, 2015, compared with the same period in 2014; balance-sheet figures are compared with December 31, 2014.
Key financial results
| Metric | Q1 2015 | Q1 2014 / prior date |
|---|---|---|
| Net sales | $89.8 million | $100.0 million |
| Gross profit and margin | $70.4 million; 78.5% | $73.2 million; 73.2% |
| Operating loss | $7.2 million | $0.03 million |
| Net loss | $8.4 million; $0.45 per diluted share | $2.5 million; $0.14 per diluted share |
| Operating cash flow | $4.9 million provided | $10.2 million used |
| Cash and cash equivalents | $29.8 million | $36.8 million at Dec. 31, 2014 |
| Restricted cash | $27.3 million | $34.4 million at Dec. 31, 2014 |
| Total current assets / current liabilities | $235.0 million / $69.4 million | $256.4 million / $66.4 million at Dec. 31, 2014 |
| Debt | No borrowings under the term or revolving facilities | No borrowings at Dec. 31, 2014 |
Cash, including restricted cash, totaled $57.0 million at quarter-end. Investing activities used $15.6 million, including the $15.0 million eNeura note investment and $5.1 million of property and equipment expenditures, partly offset by $4.8 million of asset-sale proceeds. Foreign-exchange movements reduced cash by $5.3 million.
Changes versus the prior comparable period
- Sales declined 10% as reported and 7% at constant currency; foreign-currency translation reduced sales by $2.9 million.
- BioStim sales rose 2% to $37.7 million and Biologics rose 7% to $14.0 million. Extremity Fixation fell 19% reported (9% constant currency) to $21.8 million; Spine Fixation fell 29% to $16.3 million.
- Gross margin improved 5.3 percentage points, attributed to product mix and lower inventory charges from improved inventory management and higher forecast demand.
- Sales and marketing expense increased $3.1 million to $44.3 million, and general and administrative expense increased $3.9 million to $21.2 million. Accounting-review and restatement costs declined $2.4 million to $5.9 million.
- Operating cash flow improved by $15.2 million year over year, principally as working capital provided $4.6 million of cash versus using $15.0 million a year earlier.
Outlook, commentary and material risks
- For full-year 2015, management forecast net sales of $385–$390 million, equivalent to a constant-currency decline of 0.7% to growth of 0.6%, and reported decline of 4.3% to 3.1%. Adjusted EBITDA guidance was $55–$58 million.
- Management cited rebuilding and expanding sales channels, restructuring the domestic Spine Fixation channel, and investing in infrastructure and internal controls. Project Bluecore is a multi-year systems and process initiative expected to continue through mid-2017; $4 million was paid in Q1, partly capitalized.
- The $100 million revolving-credit commitment had been reduced from $200 million; no facility borrowings were outstanding. Any revolving balance would be due August 30, 2015. The filing identifies facility expiry in August 2015 as a risk. Cash held within certain subsidiaries is restricted in its use and access by other group entities.
- Disclosure controls and procedures were deemed ineffective at March 31, 2015 because material weaknesses in financial reporting controls remained. Areas included distributor revenue recognition, receivables and inventory reserves, oversight of foreign subsidiaries, and manual journal entries. Remediation was ongoing and incomplete.
- The company reported an SEC formal investigation related to accounting matters and restatements, securities class-action litigation, and an ongoing review of potential improper payments involving its Brazil subsidiary. Possible losses could not be reasonably estimated. It also disclosed indemnification exposure for certain product-liability claims involving former subsidiary Breg, including a $5.7 million accrual for specified cold-therapy liabilities.
- The eNeura agreement provided an exclusive 18-month option to acquire the company; Orthofix paid a non-refundable $0.3 million fee and received a $15.0 million convertible note accruing interest at 8%. The note was classified as a Level 3 available-for-sale debt security.
Most important facts for investors to verify
- Whether sales declines in Spine Fixation and Extremity Fixation stabilize, and whether the stated full-year sales and adjusted EBITDA outlook is achieved.
- Progress and completion of internal-control remediation, and any further restatements, SEC actions or related litigation outcomes.
- Availability and terms of financing after the revolving facility’s August 2015 expiry, given restricted cash and the absence of outstanding debt at quarter-end.
- Recoverability and valuation of the eNeura note, and whether Orthofix exercises its acquisition option.
- Potential financial exposure from the Brazil review and Breg-related claims; the filing does not provide a clear estimate for several of these contingencies.